Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Share-based Compensation: 2023-2025

Historic Share-based Compensation for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to $2.6 million.

  • Contineum Therapeutics' Share-based Compensation rose 12.13% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 84.62%. This contributed to the annual value of $6.8 million for FY2024, which is 206.62% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Share-based Compensation of $2.6 million as of Q3 2025, which was up 6.24% from $2.4 million recorded in Q2 2025.
  • Contineum Therapeutics' Share-based Compensation's 5-year high stood at $2.6 million during Q1 2025, with a 5-year trough of $477,000 in Q3 2023.
  • Moreover, its 3-year median value for Share-based Compensation was $1.5 million (2024), whereas its average is $1.5 million.
  • Data for Contineum Therapeutics' Share-based Compensation shows a peak YoY surged of 380.29% (in 2024) over the last 5 years.
  • Over the past 3 years, Contineum Therapeutics' Share-based Compensation (Quarterly) stood at $759,000 in 2023, then surged by 196.57% to $2.3 million in 2024, then climbed by 12.13% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $2.4 million for Q2 2025, and $2.6 million during Q1 2025.